FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)

Linda Rider

Drug Safety Conversation (PDF – 166 KB) 11-22-2022 Fda Drug Safety Interaction The U.S. Foodstuff and Drug Administration (Fda) is investigating the threat of intense hypocalcemia with critical outcomes, such as hospitalization and demise, in clients with superior kidney disorder on dialysis treated with the osteoporosis drugs Prolia (denosumab). Our […]

Subscribe US Now